(Q37120335)

18 August 2017

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia (English)

1 reference

18 August 2017

0 references

1 reference

8

David A Rizzieri

1 reference

18 August 2017

Tod A Morris

1

1 reference

18 August 2017

Carlos M DeCastro

2

1 reference

18 August 2017

Louis F Diehl

3

1 reference

18 August 2017

Jon P Gockerman

4

1 reference

18 August 2017

Anand S Lagoo

5

1 reference

18 August 2017

Zhiguo Li

6

1 reference

18 August 2017

Joseph O Moore

7

1 reference

18 August 2017

Arati V Rao

9

1 reference

18 August 2017

7 October 2012

1 reference

18 August 2017

1 reference

18 August 2017

37

1 reference

18 August 2017

1

1 reference

18 August 2017

28-31

1 reference

Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3753071

Age and acute myeloid leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3753071

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3753071

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3753071

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3753071

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3753071

Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3753071

Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23046833

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.LEUKRES.2012.09.016

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

23046833

1 reference